Clinical Trials Arena December 16, 2024
GenAI could aid clinical trial design, feasibility and site selection, patient recruitment, analysis and regulatory submission.
Generative artificial intelligence (GenAI) has the potential to revolutionise clinical development – and certain key steps will help to unlock its full impact – according to a new report.
The ‘Intelligent Clinical Trials: Using Generative AI to Fast-Track Therapeutic Innovations‘ report, published by the World Economic Forum in collaboration with consultancy company ZS, considers the potential of GenAI in the clinical trials sector and assesses the primary obstacles to adoption.
It states: “With smart investments and an enabling environment, GenAI can help development teams optimise trial design, improve trial feasibility and site selection, overhaul clinical operations, automate data analysis and speed up and errorproof...
Today's Sponsors
Today's Sponsor